2008+ Deals w Upstream Tags.xlsx
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZAAABAC
1
Deal DateLicensorCommercialization Client Co.BiosciDB Deal LinkDeal SubjectDeal Size ($M)Upfront Cash ($M)Total Payments thru Launch ($M)Maximum Royalty (%)Stage at Deal SigningDeal TypeDeal SourceUpstream Deal(s) TagUpstream Deal DateUpstream Licensor CategoryUpstream LicensorUpstream Client Co.BiosciDB Upstream LinkUpstream Deal SubjectDeal Size ($M)Upfront Cash ($M)Total Payments thru Launch ($M)Maximum Royalty (%)Sublicense Share (%)Sublicense Share TagStage at Upstream Deal SigningUpstream Deal TypeUpstream Deal SourceChanges to Upstream Deal Related to Downstream Event(s)
2
9/2017CytomX TherapeuticsAmgenDeal
Probody T-cell engaging bispecific program against EGFRxCD3 plus three addt'l undisclosed targets
515.00 40.00 515.00 Preclinical
Co-Development, Co-Promotion, Equity, License, Option
SEC RedactedTag8/1/2010Research Institution
University of California, UC Santa Barbara
CytomX TherapeuticsDeal
Masks and protease-cleavable linkers for Probody therapeutics
1.080.001.082.00%5-15TagDiscovery
License, Equity
SEC Full
157K Cytomx shares paid to UCSB in 2013 to reduce sublicense share in connection with Amgen deal
3
7/2017CellectisCalyxtDeal
Talen gene editing technology for agriculture and feed ingredients
20.00 20.00 3.00 OtherEquity, LicenseSEC FullTag1/1/2011Research InstitutionUniversity of MinnesotaCellectisDeal
Inventions related to TAL effector-mediated DNA recognition and cleavage
0.25CONDiscoveryLicenseSEC RedactedSublicense Revenue definition amended in 5/12
4
7/2017RadiusTeijin PharmaDealAbaloparatide-SC for osteoporosis in Japan 50.00 10.00 50.00 Phase III
Co-Development, Co-Promotion, License, Option
SEC RedactedTag9/1/2005Commercial EntityIpsenRadiusDeal
BA058 PTHrP analog for osteoporosis and several Ipsen formulations ex-Japan
41.250.255.00%CONPhase I
License, Co-Promotion
SEC Redacted
5
7/2017Tesaro
Takeda, Millennium Pharmaceuticals
Deal
Niraparib PARP inhibitor in Japan, ex-prostate cancer in S. Korea, Taiwan, Russia & Australia
340.00 100.00 240.00 Phase IIILicense, SupplySEC RedactedTag5/1/2012Commercial EntityMerckTesaroDeal
Niraparib (MK-4827) PARP inhibitor and backup compound, MK-2512 for cancer
181.007.0093.5014.00%Phase I
License, Co-Promotion
FOIA(see Tesaro/Janssen 4/16)
6
3/2017Editas MedicineAllerganDeal
Leber Congenital Amaurosis (LCA10) and up to 5 CRISPR genome-editing ocular programs
337.00 90.00 Preclinical, Orphan Indication
Co-Development, Co-Promotion, License, Option
SEC RedactedTag8/1/2016Research InstitutionMass General HospitalEditas MedicineDeal
CRISPR genome editing technology related to high-fidelity Cas9 nucleases and Cas9 PAM variants
9.650.754.75DiscoveryLicenseSEC Redacted
7
3/2017Editas MedicineAllerganDeal
Leber Congenital Amaurosis (LCA10) and up to 5 CRISPR genome-editing ocular programs
Preclinical, Orphan Indication
Co-Development, Co-Promotion, License, Option
SEC RedactedTag8/1/2014Research InstitutionMass General HospitalEditas MedicineDeal
IP related to CRISPR/Cas9 and TALENs genome editing systems
5.600.103.80Discovery
License, Equity
SEC Redacted
8
3/2017Editas MedicineAllerganDeal
Leber Congenital Amaurosis (LCA10) and up to 5 CRISPR genome-editing ocular programs
Preclinical, Orphan Indication
Co-Development, Co-Promotion, License, Option
SEC RedactedTag12/1/2016Research Institution
Wageningen University, University of Tokyo, Broad Institute, Harvard, MIT
Editas MedicineDeal
Cpf1 compositions of matter and their use for gene editing
251.0010.0036.00CONDiscovery
License, Equity, Loan
SEC Redacted
9
2/2017Eyegate PharmaceuticalsValeant PharmaceuticalsDeal
EyeGate II Delivery System & EGP-437 combination product for post-op ocular pain & inflammation
103.00 4.00 103.00 FormulationCo-Development, LicenseSEC RedactedTag12/1/1997Research InstitutionUniversity of MiamiEyegate PharmaceuticalsDeal
Device for the intraocular transfer of active products by iontophoresis
0.160.060.162.00%DeviceLicenseFOIA
10
1/2017Calithera BiosciencesIncyteDeal
CB-1158 (arginase inhibitor) for hematology and oncology indications
483.00 45.00 483.00 Phase I
Co-Development, Co-Promotion, Equity, License, Option
SEC RedactedTag12/1/2014Commercial EntityMars SymbioscienceCalithera BiosciencesDeal
Small molecule arginase inhibitors to be developed into immuno-oncology therapy for cancer
118.900.3023.90PreclinicalLicenseSEC Redacted
11
1/2017Forward PharmaBiogenDeal
IP related to dimethyl fumarate for multiple sclerosis
1,250.00 1,250.00 1,250.00 20.00 Approved, Orphan IndicationLicense, SettlementSEC FullTag5/1/2010Commercial EntityAditechForward PharmaDeal
DMF (dimethyl fumarate) slow release formulation for multiple sclerosis
25.0025.0025.002.00%20.0Tag
Preclinical, Formulation
Asset Purchase
SEC Full
$25M from Biogen sublicense & add'l sublicense share added per 1/17 Assignment (see Tag)
12
1/2017Gilead, Kite PharmaDaiichi SankyoDeal
Axicabtagene ciloleucel (KTE-C19) for non-Hodgkin lymphoma & option to KITE-718 in Japan
450.00 50.00 270.00 Phase II, Orphan IndicationLicense, OptionSEC RedactedTag12/1/2014Research InstitutionNIHGilead, Kite PharmaDeal
IP related to T-cell receptor-based products for cancers associated with HPV infection
13.430.436.43Phase ILicenseSEC Redacted
13
1/2017
Ionis Pharmaceuticals, Akcea Therapeutics
NovartisDeal
AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular disease
1,655.00 75.00 1,105.00 Phase II, Phase I
Co-Development, Co-Promotion, Equity, License, Option
SEC RedactedTag1/1/2015Commercial EntityIonis PharmaceuticalsAkcea TherapeuticsDeal
Spinout of volanesorsen, APO(a)-LRx, ANGPTL3-LRx and APOCIII-LRx lipid drugs
150.0015.0025.00%50.0Tag
Phase III, Phase II, Preclinical
Development, License, Equity, Loan
SEC Full
$15M from Novartis sublicense & 50% of milestones per 1/17 amendment (see Tag)
14
1/2017NovanSato PharmaceuticalDeal
SB204 (nitric oxide-releasing gel) for acne in Japan
42.40 10.80 34.60 Phase IIILicense, SupplySEC RedactedTag7/1/2007Research InstitutionUniversity of North CarolinaNovanDealNVN1000 nitricil compounds for acne and derm0.430.010.43CONLead Molecule
License, Equity
SEC Redacted
15
12/2016ConatusNovartisDeal
Emricasan (pan-caspase protease inhibitor) for NASH cirrhosis
722.00 50.00 722.00 Phase II
Co-Development, Co-Promotion, License, Loan, Option
SEC RedactedTag7/1/2010Commercial Entity
Pfizer, Idun Pharmaceuticals
ConatusDeal
Purchase of Idun's IDN-6556 (Emricasan) for treatment of liver disease
19.250.2519.250.50%20.0TagPhase II
Asset Purchase, Loan
SEC Redacted
16
12/2016CymaBay Therapeutics
Kowa, Kowa Pharmaceuticals America
DealArhalofenate for gout in the US 205.00 5.00 205.00 Phase IILicenseSEC RedactedTag6/1/1998Commercial EntityDiaTexCymaBay TherapeuticsDealHalofenate chiral isomers for treatment of diabetes2.00%Phase I
Development, License
SEC Redacted
17
12/2016Selecta BiosciencesSpark TherapeuticsDeal
Synthetic Vaccine Particles technology for Factor VIII gene therapy plus 4 add'l targets
460.00 15.00 95.00
Lead Molecule, Discovery, Orphan Indication
Equity, License, OptionSEC RedactedTag11/1/2008Research InstitutionMITSelecta BiosciencesDealTherapeutic or prophylactic vaccine for therapy10-30Lead Molecule
License, Equity
SEC Redacted
Sublicense share 10-30% ($1.9M to MIT on Spark sublicense) per Selecta's 9Q17
18
10/2016Infinity PharmaceuticalsVerastemDeal
Duvelisib (IPI-145) PI3k-delta/gamma inhibitor for blood cancers
28.00 28.00 Phase IIILicenseSEC RedactedTag7/1/2010Commercial EntityTakeda, IntellikineInfinity PharmaceuticalsDealDuvelisib (PI3K/mTOR pathway inihibitor) & IPI-549183.5013.50183.5011.00%50.0TagPreclinical
Co-Co, License, Option, Loan
SEC Redacted
50% to Takeda on Verastem payments, per 9/16 am (see Tag)
19
10/2016Ocular TherapeutixRegeneron PharmaceuticalsDeal
Sustained release formulation of large-molecule VEGF trap Aflibercept for wet AMD
305.00 10.00 255.00 Preclinical, FormulationCo-Development, License, OptionSEC RedactedTag4/1/2007Commercial EntityInceptOcular TherapeutixDealReSure Sealant and other ophthalmic productsLead Molecule
License, Equity
SEC Redacted
20
10/2016Summit TherapeuticsSarepta TherapeuticsDeal
Ezutromid (utrophin modulator) for Duchenne muscular dystrophy in Europe & Turkey
852.00 40.00 522.00 Phase II, Orphan Indication
Co-Development, License, Option, Supply
SEC RedactedTag11/1/2013Research InstitutionUniversity of OxfordSummit TherapeuticsDeal
MuOx and related utrophin modulators and core screening technology for DMD
Lead Molecule
Research, Option, License, Equity
SEC Redacted
21
9/2016Arrowhead PharmaceuticalsAmgenDeal
ARO-AMG1 (RNAi program) for undisclosed genetically validated cardiovascular target
19.00 5.00 19.00 Preclinical
Co-Development, Equity, License, Option, Research
SEC RedactedTag3/1/2015Commercial EntityNovartisArrowhead PharmaceuticalsDealAcquisition of RNAi research and development portfolio10.00Preclinical
Asset Purchase, License, Equity
SEC Redacted
22
9/2016Arrowhead PharmaceuticalsAmgenDeal
ARO-AMG1 (RNAi program) for undisclosed genetically validated cardiovascular target
Preclinical
Co-Development, Equity, License, Option, Research
SEC RedactedTag2/1/2009Commercial EntityMarina BiotechRocheDealsiRNA constructs IP5.005.000.50%DiscoveryLicenseFOIA
Roche paid $1M to Marina in 10/11 for agreement to assign assets, per Marina's 12/13 10-K
23
9/2016Arrowhead PharmaceuticalsAmgenDeal
ARO-LPA (RNAi for apolipoprotein A) for cardiovascular diseases
661.50 30.00 661.50 PreclinicalEquity, LicenseSEC RedactedTag3/1/2015Commercial EntityNovartisArrowhead PharmaceuticalsDealAcquisition of RNAi research and development portfolioPreclinical
Asset Purchase, License, Equity
SEC Redacted
24
9/2016Arrowhead PharmaceuticalsAmgenDeal
ARO-LPA (RNAi for apolipoprotein A) for cardiovascular diseases
PreclinicalEquity, LicenseSEC RedactedTag2/1/2009Commercial EntityMarina BiotechRocheDealsiRNA constructs IPDiscoveryLicenseFOIA
Roche paid $1M to Marina in 10/11 for agreement to assign assets, per Marina's 12/13 10-K
25
9/2016TesaroZai LaboratoryDeal
Niraparib (PARP inhibitor) for ovarian cancer in China
54.50 15.00 54.50 Phase III
Co-Promotion, Development, License, Option
SEC RedactedTag5/1/2012Commercial EntityMerckTesaroDeal
Niraparib (MK-4827) PARP inhibitor and backup compound, MK-2512 for cancer
Phase I
License, Co-Promotion
FOIA
in 4/16, Merck Co-promotion right dropped & Net Sales def amended
26
9/2016VIVUSMetuchenDeal
Stendra (Avanafil oral PDE5 inhibitor) for erectile dysfunction in NA, SA & India
70.00 70.00 70.00 ApprovedLicense, SupplySEC RedactedTag12/1/2000Commercial EntityMitsubishi, TanabeVIVUSDeal
Spedra (avanafil TA-1790 PDE-5 inhibitor) for erectile dysfunction ex-Japan, China & PacRim
40.005.0034.0018.00%Phase II
Development, License, Supply, Co-Promotion
FOIA
27
8/2016MEI PharmaHelsinnDealPracinostat (HDAC inhibitor) for leukemia 469.00 20.00 469.00 Phase IICo-Development, Equity, LicenseSEC RedactedTag8/1/2012Commercial EntityS*BIOMEI PharmaDeal
Pracinostat HDAC inhibitor for solid tumors and hematologic disorders
76.2046.202.00%Phase II
Asset Purchase, Equity
SEC Full
28
8/2016Menlo Therapeutics
Japan Tobacco, Torii Pharmaceutical
Deal
Serlopitant NK-1 receptor antagonist for chronic pruritus in Japan
54.00 11.00 39.00 Phase IILicenseSEC RedactedTag12/1/2012Commercial EntityMerckMenlo TherapeuticsDeal
Serlopitant (NK1-R antagonist) for pruritus and dermatological conditions
76.001.0076.00Phase II
License, Equity
SEC Redacted
29
7/2016PfenexJazz PharmaceuticalsDeal
Undisclosed hematology product candidates including option to recombinant pegaspargase product
181.00 15.00 56.00 PreclinicalCo-Development, License, OptionSEC RedactedTag11/1/2009Commercial EntityDow ChemicalPfenexDeal
Spinoff of Pseudomonas fluorescens technology for oral immunizaton by RNA viruses
Discovery
Asset Purchase, License, Equity
SEC Redacted
30
5/2016
BioDelivery Sciences International
Collegium PharmaceuticalDeal
Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain in US
25.50 2.50 8.50 Filed, FormulationLicense, TerminationSEC RedactedTag7/1/2005Commercial Entity
Clinical Development Capital
BioDelivery Sciences International
Deal
BEMA (fentanyl buccal soluble film) for breakthrough cancer pain
Preclinical, Formulation
LicenseSEC Redacted
31
4/2016Aratana TherapeuticsLilly, ElancoDeal
Galliprant (grapiprant tablets) for osteo pain in dogs
149.00 45.00 74.00 Approved
Co-Development, Co-Promotion, License, Supply
SEC RedactedTag12/1/2010Commercial EntityRaQualia PharmaAratana TherapeuticsDeal
Entyce (AT-002 capromorelin ghrelin agonist) for weight gain in dogs and cats
12.904.35Lead MoleculeLicenseSEC Redacted
32
4/2016CytomX TherapeuticsAbbVieDeal
Probody-drug conjugates against CD71 for solid and hematologic cancers
490.00 20.00 490.00 Preclinical
Co-Development, Co-Promotion, License, Option, Research
SEC RedactedTag8/1/2010Research Institution
University of California, UC Santa Barbara
CytomX TherapeuticsDeal
Masks and protease-cleavable linkers for Probody therapeutics
TagDiscovery
License, Equity, Loan
SEC Full
157K Cytomx shares paid to UCSB in 2013 to reduce sublicense share in connection with Amgen deal
33
4/2016CytomX TherapeuticsAbbVieDeal
Probody-drug conjugates against two oncology targets
285.00 10.00 285.00 DiscoveryLicense, ResearchSEC RedactedTag8/1/2010Research Institution
University of California, UC Santa Barbara
CytomX TherapeuticsDeal
Masks and protease-cleavable linkers for Probody therapeutics
TagDiscovery
License, Equity, Loan
SEC Full
157K Cytomx shares paid to UCSB in 2013 to reduce sublicense share in connection with Amgen deal
34
4/2016Intellia TherapeuticsRegeneron PharmaceuticalsDeal
CRISPR/Cas gene editing technology for transthyretin amyloidosis plus up to 9 other targets
445.00 75.00 260.00 Discovery, Orphan Indication
Co-Development, Co-Promotion, Equity, License, Option, Research
SEC RedactedTag7/1/2014Commercial EntityCaribou BiosciencesIntellia TherapeuticsDeal
Launch of Intellia Therapeutics and exclusive rights to CRISPR-Cas9 gene editing technology platform
Discovery
License, Equity, Loan
SEC Redacted
35
4/2016Progenics PharmaceuticalsBayerDeal
PSMA antibody technology combined with targeted thorium conjugate technology for prostate cancer
183.00 4.00 53.00 PreclinicalLicenseSEC RedactedTag6/1/1999Commercial Entity
EUSA Pharma, Jazz Pharmaceuticals, Cytogen
Progenics PharmaceuticalsDealPSMA LLC for prostate cancer5.102.105.10Discovery
Joint Venture, License
FOIA50/50 profit split until 4/006 termination
36
4/2016Progenics PharmaceuticalsBayerDeal
PSMA antibody technology combined with targeted thorium conjugate technology for prostate cancer
PreclinicalLicenseSEC RedactedTag2/1/2001Commercial EntityAmgen, Abgenix
EUSA Pharma, Jazz Pharmaceuticals, Cytogen, Progenics Pharmaceuticals
Deal
XenoMouse technology for prostate specific membrane antigen
7.107.10Discovery
Research, Option, License
SEC Redacted
37
4/2016TesaroJohnson & Johnson, JanssenDeal
Niraparib (PARP inhibitor) for prostate cancer ex-Japan
500.00 35.00 500.00 Phase IIIEquity, LicenseSEC RedactedTag5/1/2012Commercial EntityMerckTesaroDeal
Niraparib (MK-4827) PARP inhibitor and backup compound, MK-2512 for cancer
Phase I
License, Co-Promotion
FOIA
in 4/16, Merck Co-promotion right dropped & Net Sales def amended
38
3/2016AVEO PharmaceuticalsCANbridge Life SciencesDeal
AV-203 (anti-ErbB3 antibody) for esophageal cancer ex-NAFTA
134.00 2.00 44.00 Phase ILicenseSEC RedactedTag9/1/2007Commercial EntityCephalon, Teva, EvoGenixAVEO PharmaceuticalsDeal
Superhumanized antibodies platform for designated targets
DiscoveryLicenseSEC Redacted
39
3/2016Regeneron PharmaceuticalsBayerDeal
Nesvacumab and aflibercept combination for ophthalmic indications ex-US
130.00 50.00 130.00 Phase II, FormulationCo-Development, LicenseSEC RedactedTag5/1/2013Commercial EntityRoche, Genentech
Regeneron Pharmaceuticals, Bayer
DealVEGF antagonist IP ex-US60.005.50%Lead Molecule
License, Settlement
SEC Full
40
2/2016Braeburn PharmaceuticalsKnight TherapeuticsDeal
Probuphine (buprenorphine subdermal implant) for opioid dependence in Canada
Phase III, FormulationDistribution, SublicenseSEC RedactedTag12/1/2012Commercial EntityTitan PharmaceuticalsBraeburn PharmaceuticalsDeal
Probuphine (buprenorphine subdermal implant) for opioid dependence in NA
270.0015.75105.00Phase III, Formulation
Co-Dev, License, Equity
SEC Redacted
41
1/2016Mersana TherapeuticsTakeda, MillenniumDeal
XMT-1522 (HER2 Ab) Fleximer antibody-drug conjugate platform ex-NA
354.50 26.50 281.50 PreclinicalCo-Development, Equity, LicenseSEC RedactedTag7/1/2012Commercial EntityAdimabMersana TherapeuticsDealHER2 antibody-drug conjugate28.001.5026.50CONDiscovery
Co-Dev, License
SEC Redacted
42
12/2015AVEO PharmaceuticalsEUSA PharmaDeal
Tivozanib for renal cell carcinoma in EU, South America, South Africa & Oceania
386.50 2.50 51.50 Phase III, Orphan IndicationCo-Development, License, OptionSEC RedactedTag12/1/2006Commercial EntityKyowa Hakko Kirin, KirinAVEO PharmaceuticalsDeal
Tivozanib (KRN951 oral VEGF receptor inhibitor) for solid tumors ex-Asia & mideast
65.005.0065.0030.0Phase ILicenseSEC Redacted30% sublicene revenue sharing, per Aveo's 9Q17
43
11/2015Spectrum PharmaceuticalsMundipharmaDeal
Zevalin (ibritumomab tiuxetan) for lymphoma in Japan, Middle East, Africa & Latin America
20.00 15.00 18.00 Approved, Orphan IndicationAsset Purchase, SupplySEC RedactedTag1/1/2012Commercial EntityBayerSpectrum PharmaceuticalsDeal
ZEVALIN (ibritumomab tiuxetan) injection for non-Hodgkin's lymphoma ex-US
25.4025.4025.4020.00%Approved
Asset Purchase, License
SEC Redacted
44
10/2015Regenxbio
Avalanche Biotechnologies, Adverum Biotechnologies, Annapurna Therapeutics
Deal
AAVrh10 vector for alpha-1 anti-trypsin (A1AT) deficiency and allergy
20.00 20.00 Discovery, Orphan IndicationLicense, OptionSEC RedactedTag2/1/2009Research InstitutionUniversity of PennsylvaniaRegenxbioDeal
IP covering recombinant adeno-associated viral (rAAV) vectors
DiscoveryLicenseSEC Redacted
45
10/2015Regenxbio
Avalanche Biotechnologies, Adverum Biotechnologies, Annapurna Therapeutics
Deal
AAVrh10 vector for alpha-1 anti-trypsin (A1AT) deficiency and allergy
Discovery, Orphan IndicationLicense, OptionSEC RedactedTag3/1/2009Commercial EntityGlaxoSmithKlineRegenxbioDealAAV gene delivery technologyDiscovery
License, Equity
SEC Redacted
46
8/2015
AVEO Pharmaceuticals, Aveo Oncology
NovartisDealAV-380 (anti-GDF15 antibody) for cachexia 326.45 18.45 176.45 PreclinicalLicenseSEC RedactedTag7/1/2012Research InstitutionSt Vincent’s HospitalAVEO PharmaceuticalsDeal
Antibodies against Macrophage Inhibitory Cytokine for treatment of cancer anorexia/cachexia
19.600.7019.60CONLead MoleculeLicenseSEC Redacted
License restated 8/15 w higher milestones & $1.5M sublicense fee
47
8/2015
AVEO Pharmaceuticals, Aveo Oncology
NovartisDealAV-380 (anti-GDF15 antibody) for cachexiaPreclinicalLicenseSEC RedactedTag9/1/2007Commercial EntityCephalon, Teva, EvoGenixAVEO PharmaceuticalsDeal
Superhumanized antibodies platform for designated targets
DiscoveryLicenseSEC Redacted
48
8/2015
AVEO Pharmaceuticals, Aveo Oncology
NovartisDealAV-380 (anti-GDF15 antibody) for cachexiaPreclinicalLicenseSEC RedactedTag9/1/2013Commercial EntitySelexisAVEO PharmaceuticalsDealCommercial use of AV-380 mammalian cell lineReagentLicenseSEC Redacted
49
8/2015Inovio PharmaceuticalsAstraZeneca, MedImmuneDeal
INO-3112 (DNA-based cancer vaccine) for immunotherapy of HPV-associated cancers
727.50 27.50 727.50 Phase I, Preclinical
Co-Development, License, Research
SEC RedactedTag4/1/2007Research InstitutionUniversity of Pennsylvania
Inovio Pharmaceuticals, VGX Animal Health
DealHIV, HPV, HCV vaccines3.801.303.80CONPhase ILicenseSEC Redacted
50
7/2015
Applied Genetic Technologies
BiogenDeal
XLRS and XLRP gene therapy programs for genetic eye diseases plus option to discovery programs
1,184.00 94.00 1,056.50
Phase I, Preclinical, Discovery, Orphan Indication
Co-Development, Co-Promotion, Equity, License, Option, Research
SEC RedactedTag10/1/2003Research Institution
University of Florida, Johns Hopkins
Applied Genetic Technologies
Deal
HSV construct and various compositions for gene therapy
0.500.50CONTagLead Molecule
License, Equity
SEC Redacted
Sublicense terms amended 11/04, 6/15 & 7/15 (see Tag)
51
7/2015
Applied Genetic Technologies
BiogenDeal
XLRS and XLRP gene therapy programs for genetic eye diseases plus option to discovery programs
Phase I, Preclinical, Discovery, Orphan Indication
Co-Development, Co-Promotion, Equity, License, Option, Research
SEC RedactedTag1/1/2006Research InstitutionUniversity of Alabama
Applied Genetic Technologies
DealGene delivery based products4.704.70CONTagDiscoveryLicenseSEC Redacted
License converted to exclusive 6/15 and sublicense terms amended (see Tag)
52
7/2015
Applied Genetic Technologies
BiogenDeal
XLRS and XLRP gene therapy programs for genetic eye diseases plus option to discovery programs
Phase I, Preclinical, Discovery, Orphan Indication
Co-Development, Co-Promotion, Equity, License, Option, Research
SEC RedactedTag9/1/2012Research InstitutionUniversity of Florida
Applied Genetic Technologies
DealNovel therapeutics in the field of ophthalmology0.600.60CONLead MoleculeLicenseSEC Redacted
53
7/2015
Applied Genetic Technologies
BiogenDeal
XLRS and XLRP gene therapy programs for genetic eye diseases plus option to discovery programs
Phase I, Preclinical, Discovery, Orphan Indication
Co-Development, Co-Promotion, Equity, License, Option, Research
SEC RedactedTag11/1/2012Research InstitutionUniversity of Florida
Applied Genetic Technologies
Deal
Novel therapeutics for Achromatopsia, X-Linked Retinoschisis and X-linked Retinitis Pigmentosa
0.600.60CONLead MoleculeLicenseSEC Redacted
54
5/2015Antisense TherapeuticsStrongbridge BiopharmaDeal
COR-004 (ATL1103 antisense inhib of GH) for acromegaly & endocrine ex-Oceania
110.00 3.00 110.00 Phase II, Orphan IndicationDevelopment, Equity, LicenseSEC RedactedTag10/1/2001Commercial EntityIonis PharmaceuticalsAntisense TherapeuticsDeal
ATL1102 for multiple sclerosis and ATL1103 for growth disorders
5.00%5-33TagPreclinical
Development, License, Equity
FOIA
55
5/2015Editas MedicineJuno TherapeuticsDeal
CRISPR/Cas9 genome editing technologies to develop up to 3 CAR and TCR cell therapies for cancer
744.50 25.00 519.50 DiscoveryDevelopment, License, ResearchSEC RedactedTag10/1/2014Research Institution
Broad Institute, Harvard, MIT
Editas MedicineDeal
IP related to CRISPR/Cas9 and TALEN genome editing systems
69.000.2415.00CONDiscoveryLicenseSEC Redacted
56
5/2015Editas MedicineJuno TherapeuticsDeal
CRISPR/Cas9 genome editing technologies to develop up to 3 CAR and TCR cell therapies for cancer
DiscoveryDevelopment, License, ResearchSEC RedactedTag10/1/2014Research InstitutionDuke UniversityEditas MedicineDeal
IP related to CRISPR/Cas9 and TALEN genome editing systems
TagDiscoveryLicenseSEC Redacted
License amended 10/15 to reflect apportionment of Juno upfront (see Tag)
57
5/2015Editas MedicineJuno TherapeuticsDeal
CRISPR/Cas9 genome editing technologies to develop up to 3 CAR and TCR cell therapies for cancer
DiscoveryDevelopment, License, ResearchSEC RedactedTag8/1/2014Research InstitutionMass General HospitalEditas MedicineDeal
IP related to CRISPR/Cas9 and TALENs genome editing systems
Discovery
License, Equity
SEC Redacted
58
4/2015Clearside BiomedicalSpark TherapeuticsDeal
Microinjector technology to deliver gene therapies to the retina for macular edema
29.00 0.50 17.00 Formulation
Co-Development, License, Option, Research, Termination
SEC RedactedTag7/1/2012Research Institution
Georgia Tech, Emory University
Clearside BiomedicalDealMicroneedle for ocular procedure and tissue injections0.250.140.253.00%10.0TagDeviceLicenseFOIA
59
3/2015Bavarian NordicBristol-Myers SquibbDeal
Prostvac prostate-specific antigen-targeting cancer immunotherapy
975.00 60.00 480.00 Phase III
Co-Development, License, Option, Supply
SEC RedactedTag8/1/2008Research InstitutionNIHBavarian NordicDeal
Prostvac (prostate specific antigen peptide) as immunotherapy vaccine
Phase IILicenseSEC Redacted
60
3/2015Ziopharm, IntrexonMerck KGaA, Merck SeronoDeal
Chimeric antigen receptor T-cell (CAR-T) products for cancer
941.00 115.00 941.00 Discovery
Development, License, Option, Research
SEC RedactedTag1/1/2015Research Institution
University of Texas, MD Anderson Cancer Center
Ziopharm, IntrexonDeal
CAR T Cell, TCR, NK cell programs to develop non-viral adoptive cellular cancer immunotherapies
145.00145.00Lead Molecule
Research, License, Equity
SEC Redacted
61
2/2015PfenexPfizer, HospiraDeal
PF582 biosimilar of Lucentis (ranibizumab injection) for ophthalmic diseases worldwide
342.00 51.00 82.00 Phase I
Co-Development, License, Termination
SEC RedactedTag11/1/2009Commercial EntityDow ChemicalPfenexDeal
Spinoff of Pseudomonas fluorescens technology for oral immunizaton by RNA viruses
Discovery
Asset Purchase, License, Equity
SEC Redacted
62
2/2015Voyager TherapeuticsSanofi, GenzymeDeal
VY-AADC01, VY-FXN01 and VY-HTT01 AAV gene therapies for CNS disorders WW ex-US
845.00 65.00 465.00
Phase I, Preclinical, Orphan Indication
Co-Development, Equity, License, Option, Supply
SEC RedactedTag5/1/2014Commercial EntityRegenxbioVoyager TherapeuticsDeal
NAV vectors to develop gene therapies for ALS, Friedreich’s ataxia and Huntington’s disease
5.500.505.50CONDiscoveryLicenseSEC Redacted
63
2/2015Voyager TherapeuticsSanofi, GenzymeDeal
VY-AADC01, VY-FXN01 and VY-HTT01 AAV gene therapies for CNS disorders WW ex-US
Phase I, Preclinical, Orphan Indication
Co-Development, Equity, License, Option, Supply
SEC RedactedTag1/1/2014Research InstitutionUniversity of MassachusettsVoyager TherapeuticsDeal
Gene therapies for treatment of diseases of the central nervous system
0.34CONPhase ILicenseSEC Redacted
64
1/2015AgenusIncyteDeal
Retrocyte Display platform to develop immuno-oncology antibodies targeting GITR, OX40, LAG-3 & TIM-3
650.00 25.00 470.00 12.00 Discovery
Co-Development, Co-Promotion, Equity, License, Option, Research
SEC RedactedTag12/1/2014Research InstitutionLudwig Cancer ResearchAgenus, 4-AntibodyDeal
Retrocyte Display technology to generate fully human antibodies against cancer targets
101.001.00101.00CONLead MoleculeLicenseSEC Redacted
65
12/2014Intellia TherapeuticsNovartisDeal
CRISPR/Cas9 gene editing technology platform to engineer CARTs and HSCs
285.30 30.00 185.30 Discovery
Co-Promotion, Development, Equity, License, Option, Research
SEC RedactedTag7/1/2014Commercial EntityCaribou BiosciencesIntellia TherapeuticsDeal
Launch of Intellia Therapeutics and exclusive rights to CRISPR-Cas9 gene editing technology platform
Discovery
License, Equity
SEC Redacted
66
12/2014Syndax PharmaceuticalsKyowa Hakko KirinDeal
Entinostat (HDAC inhibitor) for breast cancer and solid tumors in Japan and Korea
100.00 17.50 75.00 Phase III
Development, Equity, License, Supply
SEC RedactedTag3/1/2007Commercial EntityBayer, Bayer ScheringSyndax PharmaceuticalsDeal
Entinostat (MS-275 & SNDX-275 HDAC inhibitor) for hematologic and solid tumor cancers
152.002.0052.00Phase ILicenseSEC Redacted
67
12/2014Zosano PharmaLillyDeal
ZP-PTH parathyroid hormone 1-34 transdermal micropatch for osteoporosis
440.00 315.00 12.00 Phase II, Formulation
Co-Development, Equity, License, Supply, Termination
FOIATag10/1/2006Commercial EntityJohnson & Johnson, ALZAZosano PharmaDeal
Needle-­free transdermal delivery of therapeutic proteins, peptides and vaccines
4.00%10-20TagPhase I
License, Equity
FOIA
68
11/2014AVEO PharmaceuticalsOphthotechDeal
Tivozanib (VEGF inhibitor) for non-oncologic ocular diseases worldwide ex-Asia
105.50 0.50 60.50 PreclinicalLicense, Option, TerminationSEC RedactedTag12/1/2006Commercial EntityKyowa Hakko Kirin, KirinAVEO PharmaceuticalsDeal
Tivozanib (KRN951 oral VEGF receptor inhibitor) for solid tumors ex-Asia & mideast
Phase ILicenseSEC Redacted30% sublicene revenue sharing, per Aveo's 9Q17
69
10/2014NewLink GeneticsRoche, GenentechDeal
GDC-0919 (NLG919 IDO inhibitor) for cancer plus discovery of next generation IDO/TDO compounds
1,139.70 150.00 839.70 22.00 Phase I, Discovery
Co-Development, Co-Promotion, License, Option, Research, Termination
FOIATag9/1/2005Research Institution
Augusta University, Medical College of Georgia
NewLink GeneticsDeal
Indoleamine-2,3-Dioxygenase and its inhibitors in Immuno-regulation
2.980.162.985.00%10-25TagLead Molecule
License, Equity
FOIA
Sublicense share amended to 25% per 7/14 Amendment
70
10/2014NewLink GeneticsRoche, GenentechDeal
GDC-0919 (NLG919 IDO inhibitor) for cancer plus discovery of next generation IDO/TDO compounds
Phase I, Discovery
Co-Development, Co-Promotion, License, Option, Research, Termination
FOIATag7/1/2005Research InstitutionLankenau InstituteNewLink GeneticsDeal
Indoleamine 2,3-dioxygenase (IDO-1) pathway inhibitor for cancer
1.400.051.402.50%10.0TagLead MoleculeLicenseFOIA
Sublicense share amended to 5% per 4/09 License
71
9/2014Infinity PharmaceuticalsAbbVieDeal
Duvelisib (IPI-145) PI3k-delta/gamma inhibitor for blood cancers
805.00 275.00 680.00 30.50 Phase III
Co-Development, Co-Promotion, License, Supply, Termination
SEC RedactedTag7/1/2010Commercial EntityTakeda, IntellikineInfinity PharmaceuticalsDealDuvelisib (PI3K/mTOR pathway inihibitor) & IPI-549TagPreclinical
Co-Co, License, Option, Loan
SEC Redacted
Paid-up cancer royalty for $57.5M per 7/14 Amendment
72
9/2014Merrimack PharmaceuticalsBaxalta, Shire, BaxterDeal
Onivyde (MM-398 nanoliposomal irinotecan) for pancreatic, glioma & solid tumors ex-US & Taiwan
970.00 100.00 720.00 22.00 Phase III
Co-Development, License, Supply
FOIATag5/1/2011Commercial EntityPharmaEngineMerrimack PharmaceuticalsDeal
Onivyde (MM­398 nanoliposomal irinotecan) for pancreatic cancer in Europe & Asia
220.0010.0090.0013.00%0-20TagPhase II
Development, License
FOIA
Add'l $7M on sublicense & sublicense share amended to 10% per 9/14 Amendment (see Tag)
73
9/2014
University of Oxford, Isis Innovation
LabCorp, SequenomDeal
IP for noninvasive prenatal genetic testing in NA, Japan, Europe and Australia
14.55 12.45 12.45 4.20 DiagnosticAsset PurchaseFOIATag10/1/2005Research Institution
University of Oxford, Isis Innovation
LabCorp, SequenomDeal
Non-invasive prenatal testing for genetic disorders in NA and EU
1.110.871.116.00%15.0TagDiagnosticLicenseFOIA
74
8/2014Immune DesignSanofi, AventisDeal
GLAAS discovery platform to develop products to treat peanut allergy
171.50 3.50 171.50 DiscoveryLicenseSEC RedactedTag7/1/2008Research Institution
Infectious Disease Research Institute
Immune DesignDealGlucopyranosyl Lipid Adjuvant technology for vaccines5.902.305.90CONLead Molecule
License, Equity
SEC Redacted
75
6/2014
Ultragenyx Pharmaceutical, Dimension Therapeutics
BayerDeal
DTX201 (Factor VIII gene therapy) for Hemophilia A
252.00 20.00 252.00 Preclinical, Orphan IndicationDevelopment, LicenseSEC RedactedTag10/1/2013Commercial EntityRegenxbio
Ultragenyx Pharmaceutical, Dimension Therapeutics
Deal
NAV vector technology to develop gene therapies for hemophilia and rare diseases
11.600.1411.60CONDiscovery
License, Equity
SEC Redacted
76
6/2014
Ultragenyx Pharmaceutical, Dimension Therapeutics
BayerDeal
DTX201 (Factor VIII gene therapy) for Hemophilia A
Preclinical, Orphan IndicationDevelopment, LicenseSEC RedactedTag2/1/2009Research InstitutionUniversity of PennsylvaniaRegenxbioDeal
IP covering recombinant adeno-associated viral (rAAV) vectors
DiscoveryLicenseSEC Redacted
77
6/2014
Ultragenyx Pharmaceutical, Dimension Therapeutics
BayerDeal
DTX201 (Factor VIII gene therapy) for Hemophilia A
Preclinical, Orphan IndicationDevelopment, LicenseSEC RedactedTag3/1/2009Commercial EntityGlaxoSmithKlineRegenxbioDealAAV gene delivery technology2.752.75CONDiscovery
License, Equity
SEC Redacted
78
5/2014CytomX TherapeuticsBristol-Myers SquibbDeal
Probody-drug conjugates against CTLA-4 and additional immuno-oncology targets
1,327.00 50.00 1,087.00 Discovery
Development, Equity, License, Research
SEC RedactedTag8/1/2010Research Institution
University of California, UC Santa Barbara
CytomX TherapeuticsDeal
Masks and protease-cleavable linkers for Probody therapeutics
TagDiscovery
License, Equity
SEC Full
157K Cytomx shares paid to UCSB in 2013 to reduce sublicense share in connection with Amgen deal
79
4/2014Regenxbio
Avalanche Biotechnologies, Adverum Biotechnologies, Annapurna Therapeutics
Deal
AAVrh10 gene vector for systemic Friedreich’s Ataxia
14.75 0.60 14.75 DiscoveryLicense, OptionSEC RedactedTag2/1/2009Research InstitutionUniversity of PennsylvaniaRegenxbioDeal
IP covering recombinant adeno-associated viral (rAAV) vectors
DiscoveryLicenseSEC Redacted
80
4/2014Regenxbio
Avalanche Biotechnologies, Adverum Biotechnologies, Annapurna Therapeutics
Deal
AAVrh10 gene vector for systemic Friedreich’s Ataxia
DiscoveryLicense, OptionSEC RedactedTag3/1/2009Commercial EntityGlaxoSmithKlineRegenxbioDealAAV gene delivery technologyDiscovery
License, Equity
SEC Redacted
81
3/2014Tracon PharmaceuticalsSanten PharmaceuticalDeal
TRC105 (anti-endoglin antibody) for opthalmic indications
165.00 10.00 82.50 Preclinical
Co-Development, Co-Promotion, License, Option
SEC RedactedTag6/1/2009Commercial EntityLonzaTracon PharmaceuticalsDeal
Manufacturing technology for TRC105 (IgG1 chimeric CD-105 anti-endoglin antibody)
Lead MoleculeLicenseSEC Redacted
82
3/2014Tracon PharmaceuticalsSanten PharmaceuticalDeal
TRC105 (anti-endoglin antibody) for opthalmic indications
Preclinical
Co-Development, Co-Promotion, License, Option
SEC RedactedTag11/1/2005Research Institution
Roswell Park Cancer Institute
Tracon PharmaceuticalsDeal
TRC105 (IgG1 chimeric CD-105 anti-endoglin antibody) for solid tumors
6.406.40Lead MoleculeLicenseSEC Redacted
83
2/2014RedHill Biopharma
Valeant Pharmaceuticals, Salix Pharmaceuticals
Deal
RHB-106 encapsulated bowel preparation product
39.00 11.50 24.00 Lead Molecule, FormulationLicenseSEC RedactedTag8/1/2010Commercial EntityGiacondaRedHill BiopharmaDeal
Myoconda for Crohn's, Heliconda for h pylori and Picoconda for bowel disorders
0.500.500.507.00%20.0TagPhase II
Asset Purchase
SEC Redacted
84
1/2014DurectImpax LaboratoriesDeal
Eladur (transdermal bupivacaine patch) for post-herpetic neuralgia pain
63.00 2.00 33.00 10.00 Phase II, Formulation
Asset Purchase, Development, License
FOIATag12/1/2006Commercial EntityImmune PharmaceuticalsDurectDeal
Transdermal patch containing bupivacaine for the treatment of back pain
10.001.007.0010.00%PreclinicalLicenseFOIA
85
1/2014Sangamo TherapeuticsBiogen, BioverativDeal
Zinc finger nuclease genome-editing technology for sickle cell disease and beta-thalassemia
313.80 20.00 146.30 Discovery, Orphan Indication
Co-Development, Co-Promotion, License, Option, Research
SEC RedactedTag5/1/1996Research InstitutionMITSangamo TherapeuticsDeal
Zinc Finger Proteins With High Affinity New DNA Binding Specificities
0.670.020.672.00%TagDiscoveryLicenseFOIA
$15K per sublicense, plus $5K AMF for each sublicense
86
1/2014Zosano PharmaNovo NordiskDeal
Transdermal semaglutide (GLP-1 analogue) using microneedle patch system for type 2 diabetes
61.00 1.00 41.60 5.00 Formulation
Development, License, Termination
FOIATag10/1/2006Commercial EntityJohnson & Johnson, ALZAZosano PharmaDeal
Needle-­free transdermal delivery of therapeutic proteins, peptides and vaccines
TagPhase I
License, Equity
FOIA
87
12/2013CapricorJohnson & Johnson, JanssenDeal
CAP-1002 cardiosphere-derived cell-based therapeutic for cardio diseases
337.50 12.50 337.50 Phase II
Development, License, Option, Termination
SEC RedactedTag6/1/2006Research InstitutionJohns HopkinsCapricorDealNovel therapeutics1.851.85CONPreclinicalLicenseSEC Redacted
88
12/2013CapricorJohnson & Johnson, JanssenDeal
CAP-1002 cardiosphere-derived cell-based therapeutic for cardio diseases
Phase II
Development, License, Option, Termination
SEC RedactedTag6/1/2006Research InstitutionUniversity of RomeCapricorDealCardiac stem cells in cardiac careCONLead MoleculeLicenseSEC Redacted
89
12/2013CapricorJohnson & Johnson, JanssenDeal
CAP-1002 cardiosphere-derived cell-based therapeutic for cardio diseases
Phase II
Development, License, Option, Termination
SEC RedactedTag1/1/2010Research Institution
Cedars-Sinai Medical Center
CapricorDeal
Cardiac stem cells, cardiospheres and cardiosphere derived cells for treatment for heart attack
CONLead MoleculeLicenseSEC Redacted
90
12/2013OncoMed PharmaceuticalsCelgeneDeal
Demcizumab (anti-DLL4 Ab), DLL4/VEGF bispecific Ab and four other cancer stem cell compounds
3,332.25 155.00 3,332.25 Phase I, Preclinical, Discovery
Co-Development, Co-Promotion, Equity, License, Option
SEC RedactedTag1/1/2001Research InstitutionUniversity of MichiganOncoMed PharmaceuticalsDealBreast cancer tumor initiating stem cellsCONDiscovery
License, Equity
SEC Redacted
91
12/2013Proteostasis TherapeuticsBiogenDeal
Usp14 inhibitors for neurodegenerative diseases
203.00 2.50 203.00 Discovery
Co-Development, Co-Promotion, Equity, License, Option, Research, Termination
SEC RedactedTag3/1/2011Research InstitutionHarvardProteostasis TherapeuticsDealUsp14 inhibitors for neurodegenerative diseases118.9015.40CONDiscovery
License, Equity
SEC Redacted
92
11/2013AstraZenecaHorizon PharmaDeal
Vimovo (naproxen/esomeprazole magnesium) for arthritis and ankylosing spondylitis in US
35.00 35.00 35.00 ApprovedAsset Purchase, License, SupplySEC RedactedTag8/1/2006Commercial Entity
Aralez Pharmaceuticals, Horizon Pharma, Pozen
AstraZenecaDeal
Vimovo (naproxen/esomeprazole fixed dose combo) for arthritis pain and inflammation ex-Japan
385.0050.00210.0017.50%Phase II
Co-Development, License
FOIA
93
11/2013CTI BioPharmaBaxalta, Shire, BaxterDeal
Pacritinib (JAK2/FLT3 inhibitor) for myelofibrosis and hematologic cancers
362.00 30.00 172.00 Phase III
Co-Development, Co-Promotion, Equity, License, Supply, Termination
SEC RedactedTag4/1/2012Commercial EntityS*BIOCTI BioPharmaDeal
Pacritinib JAK2/FLT3 inhibitor for myelofibrosis and hematologic cancers
162.5015.00162.50Phase II
Asset Purchase, Equity
SEC Redacted
94
10/2013VIVUSEndo International, AuxiliumDeal
Stendra (avanafil) PDE-5 inhibitor for erectile dysfunction in NA
300.00 30.00 45.00 18.00 Approved
Co-Development, License, Supply, Termination
FOIATag12/1/2000Commercial EntityMitsubishi, TanabeVIVUSDeal
Spedra (avanafil TA-1790 PDE-5 inhibitor) for erectile dysfunction ex-Japan, China & PacRim
Phase II
Development, License, Supply, Co-Promotion
FOIA
95
9/2013
Aralez Pharmaceuticals, Pozen
SanofiDeal
PA8140 and PA32540 omeprazole/aspirin combination products for cardiovascular disease in US
35.00 15.00 35.00 22.50 Filed, FormulationLicense, TerminationSEC RedactedTag8/1/2006Commercial Entity
Aralez Pharmaceuticals, Horizon Pharma, Pozen
AstraZenecaDeal
Vimovo (naproxen/esomeprazole fixed dose combo) for arthritis pain and inflammation ex-Japan
Phase II
Co-Development, License
FOIA
96
9/2013Inovio PharmaceuticalsRocheDeal
INO-5150 prostate cancer vaccine, INO-1800 hepatitis B vaccine and Cellectra electroporation tech.
422.50 10.00 422.50 Preclinical
Development, License, Option, Termination
SEC RedactedTag4/1/2007Research InstitutionUniversity of Pennsylvania
Inovio Pharmaceuticals, VGX Animal Health
DealHIV, HPV, HCV vaccinesPhase ILicenseSEC Redacted
97
7/2013FibroGenAstraZenecaDeal
Roxadustat (FG-4592) HIF-PH inhibitor for anemia in NAFTA, Africa and South America
1,365.50 374.00 1,040.50 Phase III
Co-Development, License, Supply
SEC RedactedTag2/1/2006Research InstitutionDana-FarberFibroGenDeal
Inhibition of hypoxia-inducible factor (HIF-alpha) for anemia
3.450.45CONLead MoleculeLicenseSEC Redacted
98
6/2013KadmonAbbVieDeal
Ribasphere (high dose ribavirin) for treatment of HCV
120.00 69.00 120.00 Approved, Formulation
Asset Purchase, Co-Development, Co-Promotion, License, Supply
SEC RedactedTag6/1/2008Commercial Entity
Cadila Healthcare, Zydus Cadila
KadmonDealHigh dose ribavirin1.101.101.10Preclinical
Asset Purchase
SEC Redacted
99
5/2013AmbrxBristol-Myers SquibbDealAntibody drug conjugates for cancer 112.00 15.00 112.00 DiscoveryDevelopment, License, ResearchSEC RedactedTag8/1/2003Research InstitutionScripps Research InstituteAmbrxDealBio-conjugation of peptides and proteinsDiscovery
License, Equity
SEC Redacted
100
5/2013CytomX TherapeuticsPfizerDeal
Probody technology with antibody-drug conjugates (ADCs) for EGFR and other cancer targets
271.20 6.00 151.20 DiscoveryLicense, Option, ResearchSEC RedactedTag8/1/2010Research Institution
University of California, UC Santa Barbara
CytomX TherapeuticsDeal
Masks and protease-cleavable linkers for Probody therapeutics
TagDiscovery
License, Equity
SEC Full
157K Cytomx shares paid to UCSB in 2013 to reduce sublicense share in connection with Amgen deal
Loading...
Main menu